Vascularization is an important step in tumour growth. Although a variety of molecules, for example, VEGF, ETS-1 or nestin have been implicated in tumour angiogenesis, the molecular mechanisms of vessel formation are not fully characterized. We showed that the Wilms' tumour suppressor WT1 activates nestin during development. Here we tested whether WT1 might also be involved in tumour angiogenesis. Endothelial WT1 expression was detected in 95% of 113 tumours of different origin. To analyse the function of WT1 in endothelial cells, we used an RNAi approach in vitro and showed that inhibition of WT1 reduces cell proliferation, migration and endothelial tube formation. On a molecular level, WT1 silencing diminished expression of the ETS-1 transcription factor. WT1 and ETS-1 shared an overlapping expression in tumour endothelia. The ETS-1 promoter was stimulated approximately 10-fold by transient co-transfection of a WT1 expression construct and WT1 bound to the ETS-1 promoter in chromatin immunoprecipitation and electrophoretic mobility shift assays. Deletion of the identified WT1-binding site abolished stimulation of the ETS-1 promoter by WT1. These findings suggest that transcriptional activation of ETS-1 by the Wilms' tumour suppressor WT1 is a crucial step in tumour vascularization via regulation of endothelial cell proliferation and migration.
Introduction
Vascularization is an important step in the transition from a small cluster of malignant cells to a visible macroscopic tumour capable of spreading to other organs via the vasculature (reviewed by Semenza, 2003; Cohen, 2006) . The genetic program that controls this process is not well understood although it is known that tumour cells can induce angiogenesis. The reduced oxygen supply in the core of the tumour (hypoxia), which results in stabilization of hypoxia-inducible factor 1 (HIF-1) and subsequent activation of its downstream target genes, has been postulated as an important factor in this process (reviewed by Semenza, 2003) . A variety of other molecules, for example, VEGF, VEGF-R2, angiopoietins (reviewed by Cohen, 2006) , nestin (Mokry et al., 2004) and ETS transcription factors (Wernert et al., 1992) have been implicated in tumour angiogenesis. However, the major regulatory molecules, which are involved in tumour vascularization, have not been characterized in detail so far.
We identified the Wilms' tumour suppressor 1 (WT1) as an important molecule, which is transcriptionally regulated by HIF-1 (Wagner et al., 2003) . WT1 has been originally described as a tumour suppressor gene based on its mutational inactivation in a subset of paediatric renal carcinoma (nephroblastoma, Wilms' tumour). The gene encodes a zinc-finger transcription factor, which also acts as critical regulator of organogenesis (reviewed by Hohenstein and Hastie, 2006) . Under conditions of reduced oxygen supply, WT1 is activated by HIF-1 in vascular cells (Wagner et al, 2003) . More recently, we provided evidence that WT1 activates nestin, a wellknown marker of angiogenesis (Mokry et al., 2004) in cardiac and renal development (Wagner et al., 2006) .
Based on these observations, we investigated whether WT1 might play a role in angiogenesis in a broad variety of tumours of different origin. Furthermore, we characterized the functional relevance of WT1 in endothelial cells in vitro using an RNAi approach and identified ETS-1 as a novel transcriptional target of WT1 in angiogenesis.
Results
The Wilms' tumour suppressor WT1 is expressed in vessels of the most common tumours Prompted by a recent report on WT1 expression in angiogenic tumours of the skin (Timar et al., 2005) and our observation on the role of WT1 for cardiac vessel development (Wagner et al., 2005) , we reasoned that WT1 might play a general role in tumour vessel formation. We show here that vascular WT1 expression was detectable in 95% of 113 tumour samples investigated (Table 1, Figure 1 ). Tumour samples included ovary, pancreas, kidney, lung and breast cancer as well as glioblastoma, retinoblastoma and nephroblastoma. In most cases, WT1 staining of endothelial cells was nuclear ( Figure 1) . Surprisingly, WT1 could not be detected in endothelia of 1 out of 16 clear cell carcinomas of the kidney and 4 out of 12 papillary kidney carcinomas, whereas in all other tumour types investigated, WT1 was detected in small vessels to different extent (Table 1 ). The staining pattern was nearly similar when using a polyclonal or a monoclonal antibody from different suppliers on subsequent sections ( Figure 2A ). Staining was abolished by incubation with a WT1 blocking peptide (Figure 2A) . Interestingly, vascular WT1 expression was restricted to the tumour and could not be detected in healthy adjacent tissue or nontumorous control tissue ( Figure 2B ). To examine whether WT1 could be involved in the formation of new tumour vessels, we performed immunohistochemical double labelling of WT1 and proliferating cell nuclear antigen (PCNA) as a marker for cell proliferation and of WT1 and proliferating endothelial cell adhesion molecule-1 (PE-CAM-1, CD31) in pancreas carcinoma (Figures 3a-c) , glioblastoma (Figures 3d-f ) and ovary carcinoma (Figures 3g-i ). PCNA and WT1 shared a partial overlapping expression in endothelial and some smooth muscle cells of tumour vessels (Figures 3a-c) . WT1 and PECAM-1 double labelling revealed that approximately 50% of the proliferating vessels are WT1-positive (Figures 3d-f) . The high-power magnification confirmed that WT1 is indeed expressed mainly in endothelial cells of the tumour vessel (Figures 3g-i) .
WT1 is required for endothelial cell migration, proliferation and vascular formation To characterize the functional role of WT1 in endothelial cells, we used an in vitro silencing approach in human umbilical endothelial cells (HUVECs). Different combinations of three independent WT1 stealth RNAi oligonucleotides were used and their efficiency in WT1 silencing was compared to control RNAi-transfected cells ( Figure 4A ). For subsequent experiments, the combination of RNAi oligonucleotide-1 and -2 was transfected and efficient silencing confirmed for each individual experiment by western blotting. Silencing of WT1 inhibited endothelial cell migration significantly in the transwell assay ( Figure 4B ). To investigate whether this reduced migration might be associated with altered proliferation, we performed immunostainings Figure 4C ). To clarify whether apoptosis might contribute to the disturbed migration of WT1-silenced endothelial cells, we used TdT-dUTP terminal nick-end labelling (TUNEL) followed by counting of positive cells. In addition, exposure of phosphatidylserine in apoptotic cells was detected by annexin V staining followed by fluorescence-activated cell sorting (FACS). With these two independent methods, no significant differences in apoptosis between WT1-silenced and control cells could be detected ( Figure 4D ). Furthermore, we investigated the effect of WT1 silencing on tubular network formation in Matrigel cultures as an in vitro angiogenesis assay. Tube formation of WT1-silenced endothelial cells was nearly abolished when compared to control-transfected cells, which was also reflected in the significantly lower number of endothelial tube branching points ( Figure 4E ).
WT1 silencing inhibits nestin expression in endothelial cells
As we could show recently that nestin, which is regarded as a marker of neovascularization (Aihara et al., 2004; Mokry et al., 2004) , is expressed in the developing heart and kidney and regulated by WT1, we reasoned that nestin might act downstream of WT1 also in endothelial cells and in tumour vessels. Indeed, inhibition of WT1 expression by stealth RNAi significantly reduced nestin protein expression in endothelial cells as determined by western blotting ( Figure 5A ). Using immunohistochemical double labelling for nestin and WT1, we could detect an overlapping expression of both proteins in endothelia of different tumours. Examples for this overlapping expression in bladder carcinoma and glioblastoma are shown in Figures 5B and C.
The ETS-1 transcription factor is regulated by WT1
The transcription factor ETS-1 was described as an important regulator of tumour angiogenesis (Wernert et al., 1992 , for review see Seth and Watson, 2005) . To elucidate whether a direct relation between WT1 and ETS-1 in endothelial cells might exist, we performed quantitative reverse transcription (RT)-PCR for ETS-1 on RNA from WT1-silenced and control-transfected HUVECs. Expression of ETS-1 was threefold lower in WT1-silenced cells when compared to controls ( Figure 6A ). Using western blotting, we could detect the 51 and 42 kDa splice variants of ETS-1 in HUVECs and confirm downregulation of both isoforms in WT1-silenced cells on the protein level ( Figure 6B ). Immunohistochemical double labelling of tumour samples revealed an overlapping expression of both proteins tumour endothelia ( Figures 6C and D) . As reported earlier, WT1 showed some additional expression in vascular smooth muscle cells (Wagner et al., 2002) . To investigate whether WT1 might be able to directly transcriptionally activate ETS-1, we cloned the published mouse ETS-1 promoter (Jorcyk et al., 1997) into a luciferase reporter vector and performed transient co-transfection experiments with expression plasmids encoding the WT1(ÀKTS) or WT1( þ KTS) splice variants as described by Wagner et al. (2005) . HEK293 cells were chosen, because low levels of WT1 are transcribed in these cells, suggesting that the transacting factors required for normal WT1 expression are operating in this cell line. Furthermore, HUVECs could not be used, because transfection efficiencies for plasmid constructs were extremely low in our hands. WT1(ÀKTS) stimulated the activity of the ETS-1 promoter approximately 10-fold, whereas WT1( þ KTS) had no significant effect ( Figure 7a ). In chromatin immunoprecipitation experiments using HUVECs, we could identify a binding region for WT1 protein, which contained the sequence À387 to À27 bp relative to the ATG of ETS-1, whereas a sequence from the 3 0 -untranslated region (UTR) of ETS-1 did not bind to WT1 (Figure 7b ). Using multiple alignments between mouse and human ETS-1 promoters and our identified WT1-binding site in the nephrin promoter (Wagner et al., 2004) , we predicted a binding site for WT1 in the ETS-1 promoter. Physical interaction of WT1(ÀKTS), but not WT1( þ KTS) with this element was confirmed by electrophoretic mobility shift assays. Introducing a mutation (5 0 -GCAAAAACG-3 0 ) into the core sequence (5 0 -GCGGAGGCG-3 0 ) of the oligonucleotide largely reduced the binding of WT1 protein. The identified WT1 consensus sequence from the nephrin promoter was used as positive control (Figure 7c ). In transient transfection experiments, deletion of the identified binding site abolished activation of the ETS-1 promoter by the WT1(ÀKTS) splice variant (Figure 7d ). Since angiopoietin-2 (Hasegawa et al., 2004) and the vascular endothelial growth factor receptor 2 (VEGFR2) (Elvert et al., 2003) , but not angiopoietin-1 (Brown et al., 2004) , have been described as a transcriptional targets of ETS-1, we analysed the expression of angiopoietin-1 and -2, and VEGFR2 in WT1-silenced cells, which show reduced levels of ETS-1 protein. Indeed, angiopoietin-2 and VEGFR2 expression levels were lower in WT1-silenced cells compared to controls whereas angiopoietin-1 was unchanged (Figure 7e ). In transient co-transfection experiments, the published VEGFR2 promoter was not stimulated by WT1(ÀKTS) or WT1( þ KTS) expression constructs, indicating that VEGFR2 is not directly regulated by WT1 (Figure 7f ).
Discussion
Based on the mutational inactivation of the Wilms' tumour suppressor WT1 in a small subset of nephroblastoma (Wilms' tumour), it was thought that WT1 acts as a tumour suppressor (Haber et al., 1990) , but more recently, a potential oncogenic role in a variety of WT1 activates ETS-1 in endothelial cells N Wagner et al tumours and tumour-derived cell lines have been described (for review see Hohenstein and Hastie, 2006) . Our finding of vascular WT1 expression in 95% of the investigated tumours and its requirement for endothelial cell proliferation, migration and in vitro angiogenesis supports the view of WT1 as an oncogene.
WT1 expression could be detected in vessels of most ovarian, pancreas, lung, breast, bladder and kidney carcinoma and those of nephroblastoma, retinoblastoma and glioblastoma. This suggests that WT1 might be a general marker of tumour angiogenesis. This extends a recent study, which described WT1 expression in WT1 activates ETS-1 in endothelial cells N Wagner et al angiogenic tumours of the skin (Timar et al., 2005) . The partial co-localization of WT1 with proliferation markers in tumour vessels and the diminished proliferation, migration and tube formation of endothelial cells in vitro upon silencing of WT1 is in agreement with our recent observations that WT1 is required for coronary vessel formation during embryonic development (Wagner et al., 2005) and it is expressed in microvessels after myocardial infarction, but not in vessels of adult control hearts (Wagner et al., 2002) . These data suggest that WT1 is involved actively in proliferation of endothelial cells and vessel formation rather than being only a novel endothelial cell marker.
A widely accepted marker of neovascularization is the intermediate filament protein nestin, which was detected in the majority of tumour vessels and in newly forming vessels after myocardial infarction (Aihara et al., 2004; Mokry et al., 2004) . Furthermore, mice expressing green fluorescent protein under control of nestin regulatory sequences are used to monitor formation of new vessels during tumour progression (Amoh et al., 2005) . The 
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N Wagner et al overlapping expression of WT1 and nestin in tumour vessels, the downregulation of nestin upon WT1 silencing in endothelia and the direct activation of nestin by WT1, which we reported recently (Wagner et al., 2006) suggest that WT1-dependent activation of nestin might contribute to its high expression in tumour vessels.
In addition, the ETS-1 transcription factor is well known to be expressed in endothelial cells during angiogenesis (Kola et al., 1993; Iwasaka et al., 1996) . ETS-1 belongs to the large group of ETS transcription factors, which are characterized by a conserved winged helix-turn-helix DNA-binding domain (for review see Seth and Watson, 2005) . Prompted by the partial overlapping expression pattern of WT1 and ETS-1 in the tumour vessels, we reasoned that a direct relation between both transcription factors might exist. Several lines of evidence suggest that ETS-1 represents a direct relevant target of WT1 in angiogenesis. First, silencing of WT1 inhibited ETS-1 expression. Second, WT1 and ETS-1 shared an overlapping expression in tumour endothelia in vivo. Third, WT1(ÀKTS) stimulated the activity of the ETS-1 promoter approximately 10-fold in transient co-transfection experiments. Fourth, in chromatin immunoprecipitation experiments and electrophoretic mobility shift assays, we could detect binding of WT1 protein to a promoter sequence, but not to the 3 0 -UTR of ETS-1. Finally, deletion of the identified binding site abolished stimulation of the activity of the ETS-1 promoter by WT1.
To test whether silencing of WT1 affected not only ETS-1, but also known ETS-1 downstream target genes, we analysed the expression of selected ETS-1 target genes by quantitative RT-PCR. A large variety of molecules have been described as target genes of ETS-1 (Seth and Watson, 2005) . With respect to an important role in angiogenesis, we selected VEGF receptors and angiopoietins. VEGFR2, or Flk-1 and angiopoietin-2 have been described as ETS-1 target genes (Elvert et al., 2003; Hasegawa et al., 2004) , whereas angiopoietin-1 is stimulated by ESE-1 from the group of ETS transcription factors, but not by ETS-1 (Brown et al., 2004) . In agreement with this, we detected a downregulation of angiopoietin-2 and VEGFR2, but not of angiopoietin-1 in WT1-silenced endothelial cells. The lack of stimulation of the published VEGFR2 promoter (Labrecque et al., 2003) by WT1 in transient co-transfection experiments is in accord with a stimulation of ETS-1 by WT1 and subsequent regulation of ETS-1 target genes. It is likely that for vessel formation, major regulatory pathways may converge or be interrelated because WT1 and ETS-1 are both regulated by hypoxiainducible factor-1 (Oikawa et al., 2001; Wagner et al., 2003) and both transcription factors in turn might regulate VEGF (Hashiya et al., 2004; Gao et al., 2005) .
Although a comprehensive analysis of vascular ETS-1 expression in tumours of different origin to our knowledge has not been published yet, it is interesting to note that in our study less renal papillary carcinomas than clear cell carcinomas showed WT1 expression. In comparison, Mikami et al. (2006) reported less ETS-1 expression and vascularization in papillary carcinoma compared to clear cell carcinoma. Furthermore, a better prognosis for patients with renal papillary carcinoma than for patients with renal clear cell carcinoma has been described by Cheville et al. (2003) . Whether a worse prognosis for patients might be due to a WT1-dependent upregulation of ETS-1 and subsequent increased vascularization cannot be answered at present, but the use of inducible WT1 conditional knockout mice in tumour models (currently under investigation) will shed light into the role of WT1 for tumour angiogenesis in vivo.
In summary, we have shown here that the Wilms' tumour suppressor WT1 is expressed in vessels of a broad variety of tumours and that it is involved in endothelial cell migration, proliferation and vascular formation, which might be mediated via transcriptional activation of the ETS-1 proto-oncogene.
Materials and methods

Cell culture
Human embryonic kidney (HEK) 293 cells (accession number ACC 305) were obtained from the German collection of microorganisms and cell cultures (DSMZ, Braunschweig, Germany). Nonimmortalized HUVECs were kindly provided by E Van Obberghen-Schilling. HEK293 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 IU ml À1 penicillin and 100 mg ml À1 streptomycin. HUVECs were cultured in endothelial basal medium (EBM) supplemented with 20% FCS, gentamycin (50 mg ml À1 ), amphotericin B (50 ng ml À1 ), epidermal growth factor (10 ng ml
À1
) and basic fibroblast growth factor (10 ng ml À1 ). HUVECs were used for experiments between passages 1 and 4. Media and reagents were obtained from Invitrogen (Cergy Pontoise, France).
Transient transfection experiments
For silencing of WT1 expression, HUVECs were transfected at 60-80% confluence with 10 nM of stealth RNAi doublestranded oligonucleotides (Invitrogen) of the following sequences: 1 (WT1-HSS111388), 5
0 -UUU CACACCUGUAUGUCUCCUUUGG-3 0 using jetPEI transfection reagent according to the manufacturer's instructions (Polyplus Transfection, Illkirch, France). A scrambled stealth RNAi oligonucleotide was used as control (Invitrogen). Western blotting of an aliquot of the transfected cells confirmed silencing for each experiment.
To investigate the effects of WT1 expression on ETS-1 or VEGFR2 promoter activity, a 2.5 kb fragment of the ETS-1 promoter (Jorcyk et al., 1997) was subcloned into the pGl2basic luciferase expression vector (Promega, Charbonnieres, France). A 4 kb VEGFR2 promoter construct in the luciferase expression vector was a gift from C Patterson (Labrecque et al., 2003) . Deletion of the WT1-binding site in the ETS-1 promoter was performed using the Quik Change II site-directed mutagenesis kit (Stratagene, Amsterdam, Netherlands) as described by Wagner et al. (2004) using the following primers: 5 0 -CCCTGGGCCTGGGCTCGGTCTGC ACTGCGCCAGCGCCG-3 0 (forward, reverse primer in the corresponding antisense orientation). HEK 293 cells at WT1 activates ETS-1 in endothelial cells N Wagner et al approximately 60% confluence were transfected in 60 mm tissue culture plates using Fugene 6 reagent (Roche Diagnostics, Meylan, France). About 0.3 mg of the reporter constructs together with 0.1 mg of a cytomegalovirus (CMV)-driven b-galactosidase plasmid, and 1.6 mg of the expression constructs encoding different WT1 forms were transiently co-transfected and assayed for luciferase-and b-galactosidase activity as described in detail elsewhere (Wagner et al., 2004) .
Migration assay
To determine migration of endothelial cells, HUVECs were trypsinized 24 h after siRNA transfection and seeded in the upper compartment of a modified Boyden chamber (5 Â 10 4 cells per chamber, pore size 8 mm, Corning Costar, SchipholRijk, Netherlands). The chamber was placed in a 24-well culture dish containing EBM with FCS and growth factors as described above. After 24 h, the nonmigrating cells in the upper chamber were scraped off and the migrating cells at the lower side fixed with PFA, stained with 4 0 -6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, USA) and quantified by manually counting of five random fields of five independent experiments by an investigator blinded for the identity of the experimental approach.
In vitro angiogenesis assay At 24 h after silencing, HUVECs were transferred to 96-well dishes coated with 100 ml Matrigel Basement membrane matrix (Chemicon, Millipore, Guyancourt, France). Branching points were determined after additional 24 h according to the manufacturer's instructions.
Detection of cell proliferation
At 24 h after transfecting the stealth RNAi oligonucleotides into HUVECs, the cells were split into 96-well dishes and after additional 24 h, bromodeoxyuridine was added and the cells were incubated for 3 h. Afterwards, HUVECs were fixed and BrdU detected using a mouse monoclonal anti-BrdU antibody, followed by incubation with a goat anti-mouse IgG-peroxidase conjugated secondary antibody with TMB as peroxidase substrate and spectrophotometrical reading of the plates at 450 nm according to the manufacturer's instructions (Chemicon). Alternatively, 48 h after transfection, cells were fixed and immunohistochemical detection of PCNA was performed as described (Wagner et al., 2005) with counterstaining of nuclei using DAPI (Vector Laboratories). PCNA-positive cells in five random optical fields from three independent experiments each were counted at Â 400 magnification.
Apoptosis assays
Apoptotic cells were detected by TUNEL staining 48 h after WT1 silencing using the in situ Cell Death Detection Kit (Roche Diagnostics) as described by Wagner et al. (2005) . Alternatively, HUVECs were incubated with fluorescein isothiocyanate (FITC)-conjugated annexin V (Roche Molecular Biochemicals) 48 h after transfection according to the manufacturer's instructions and counterstained with propidiumiodide to distinguish necrotic from apoptotic cell death. After repeated washes in phosphate-buffered saline (PBS), the cells were analysed in a flow cytometer (Becton Dickinson, Le Pont de Claix, France).
Immunohistochemistry and immunocytochemistry
A total of 113 paraffin-embedded tumour samples (see Table 1 ) were used for immunohistochemical detection of WT1. Paraffin sections (5 mm) were dewaxed in xylene, hydrated in ethanol series and washed in PBS. Antigen detection was performed using the EnVision þ Dual Link System-HRP(DAB þ ) from Dako Cytomation (Dako, Trappes, France) according to the manufacturer's instructions.
Polyclonal anti-WT1 antibody from rabbit (C-19, sc-192, Santa Cruz Biotechnology, Heidelberg, Germany) and monoclonal anti-WT1 antibody from mouse (clone 6F-H2, MAB 4234, Chemicon) were used in a dilution of 1:100 in PBS, 0.1% BSA, 0.1% Triton X-100. A blocking peptide (sc-192P, Santa Cruz Biotechnology) was used in the presence of the primary polyclonal antibody in a 1:10 dilution. Sections were counterstained with haematoxylin (Sigma, Lyon, France) and analysed by two independent investigators.
For immunofluorescence double labelling, sections were incubated with the polyclonal anti-WT1 antibody from rabbit mentioned above and either a monoclonal anti PCNA antibody from mouse in a 1:100 dilution (PC-10, sc-56, Santa Cruz Biotechnology), an anti ETS-1 antibody from mouse in a 1:20 dilution (clone 1G11, ab 10936, Abcam, Paris, France), a polyclonal anti PECAM-1 antibody from goat in a 1:100 dilution (M-20, sc-1506, Santa Cruz Biotechnology) or a monoclonal anti-Nestin antibody from mouse in a 1:100 dilution (MAB 5326, Chemicon). Antigens were visualized using Cy2 and Cy3 coupled secondary antibodies in a 1:150 dilution (Jackson ImmunoResearch). Slides were viewed under an epifluorescence microscope (DMLB, Leica, Wetzlar, Germany) connected to a digital camera (Spot RT Slider, Diagnostic Instruments, Livingston, Scotland) with the Spot software (Universal Imaging, Downingtown, PA, USA) or alternatively with a Zeiss 2 photon confocal microscope.
Real-time RT-PCR
RT-PCR was performed with 2 mg of total RNA as described elsewhere (Wagner et al., 2005) . Real-time PCR was performed on the Light Cycler Instrument (Roche Diagnostics) using the Platinum SYBR Green kit (Invitrogen). The following primers were used for PCR amplification: human ETS-1 (NCBI accession no. NM005238), 5 0 -GGACAAGCCTGTCATTCC TG-3 0 (forward primer), 5 0 -AAGAAACTGCCATAGCTGG ATT-3 0 (reverse primer), human angiopoietin-1 (NCBI accession no. NM_001146), 5 0 -GCAAATGTGCCCTCATGTTA-3 0 (forward primer), 5 0 -TAGATTGGAGGGGCCACA-3 0 (reverse primer), human angiopoietin-2 (NCBI accession no. NM_001147), 5 0 -TGCAAATGTTCACAAATGCTAA-3 0 (forward primer), 5 0 -AAGTTGGAAGGACCACATGC-3 0 (reverse primer), VEGFR2 (NCBI accession no. AF063658), 5 0 -CCACTCCCT TGAACACGAG-3 0 (forward primer), 5 0 -CGCCTTACGGA AGCTCTCT-3 0 (reverse primer). Expression was normalized to the individual levels of the housekeeping gene GAPDH (NCBI accession no. NM002046), 5 0 -AGCCACATCGCTCA GACAC-3 0 (forward primer), 5 0 -GCCCAATACGACCAA ATCC-3 0 (reverse primer).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was performed on HUVECs. Antibodies (2 mg each) against acetylated histone 3 (rabbit polyclonal antibody, 06-599, Upstate, Lake Placid, NY, USA) and WT1 (rabbit polyclonal antibody, C-19, Santa Cruz Biotechnology) were used. Normal rabbit serum served as a negative control and a 1:10 dilution of the 'input sample' as positive control. The histone H3 antibody was used to check for preservation of nucleosomes at the genomic locus. Following immunoprecipitation, the purified DNA was eluted in 30 ml UltraPure DNase, RNase free water (Sigma). For amplification of purified DNA fragments by PCR, 1 ml of the diluted input DNA or the immunoprecipitated DNAs were mixed with primers, DNase-free water and Red Taq Ready (reverse primer). All samples were processed in the same PCR reaction (33 cycles) at an annealing temperature of 61 1C. PCR products were electrophoresed on a 2% agarose gel yielding DNA fragments of 360 and 384 bp, respectively.
Electrophoretic mobility shift assay Electrophoretic mobility shift assays using recombinant WT1 protein were performed as described elsewhere (Wagner et al., 2004) . The 26-bp double stranded oligonucleotide (5 0 -GAG GAACGCCCTAAAGCGGAGGCGAG-3 0 ) represented the WT1 responsive element from the ETS-1 promoter. Control experiments were performed with a mutated oligonucleotide (5 0 -GAGGAACGCCCTAAAGCAAAAACGAG-3 0 , negative control) and the identified binding site in the nephrin promoter (5 0 -GGTAGGAATGGAGGAGGAGGAG-3 0 , positive control).
SDS-PAGE and western blot
Total cell lysates were prepared, electrophoresed and blotted as described in detail elsewhere (Wagner et al., 2005) . The following antibodies were used for immunodetection: polyclonal anti-WT1 antibody from rabbit (C-19, sc-846, Santa Cruz Biotechnology, 1:500 dilution in PBS, 2.5% Blotto, 0.05% Tween-20), monoclonal anti ETS-1 antibody from mouse (clone 1G11, ab 10936, Abcam, 1:100 dilution in PBS, 2.5% Blotto, 0.05% Tween-20), monoclonal anti-Nestin antibody from mouse (MAB 5326, Chemicon, 1:500 dilution in PBS, 2.5% Blotto, 0.05% Tween-20), monoclonal anti GAPDH antibody from mouse (clone 6C5, sc-32233, Santa Cruz Biotechnology, 1:1000 dilution in PBS, 2.5% Blotto, 0.05% Tween-20), peroxidase-coupled goat anti-rabbit secondary antibody (1:10 000 dilution in PBS, 2.5% Blotto, 0.05% Tween-20, Santa Cruz Biotechnology) and peroxidasecoupled rabbit anti-mouse secondary antibody (1:10 000 dilution in PBS, 2.5% Blotto, 0.05% Tween-20).
Statistical analysis
ANOVA with Bonferroni test as post-hoc test or MannWhitney tests were performed as indicated. A P-value of less than 0.05 was considered statistically significant.
